Kingworld Medicines Group Limited provided preliminary unaudited consolidated earnings guidance for the year ended December 31, 2020. For the period, the group expects to record a decrease in the profit attributable to owners of the company by approximately 70% to 75% for the year as compared to RMB 43.4 million for the year ended December 31, 2019. The board considers that the decrease in the profit attributable to owners of the company was mainly due to the following factors: as affected by the novel coronavirus (COVID-19) pandemic, the number of travellers to Hong Kong dropped drastically, along with the weakening consumption sentiments in Hong Kong, the total revenue generated from the Culturelle probiotics product series of the group in Hong Kong and Macau markets decreased by approximately 70% to 75% for the year as compared with the corresponding period in the previous year; and the increase in the administrative expenses of the group by approximately 35% to 40% for the year as compared to RMB 107.4 million for the previous year mainly due to the increase in provision for obsolete inventories as a result of the decrease in the sale of Culturelle probiotics product series of the group for the year. The board also announced that for the year, the company's non-wholly owned subsidiary, Shenzhen Dong Di Xin Technology Company Limited and the group's investment projects including its 15% equity interest investment in Dong Hua Tong Investments Limited generated profit to the group. As a result of the foregoing, the group is expected to record an increase in profit for the year of the group by approximately 1% to 5% for the year as compared to RMB 50.3 million for the previous year.